Arena Pharmaceuticals (ARNA) Tops Q2 Loss Views by 1c
Arena Pharmaceuticals (Nasdaq: ARNA) reports Q2 loss of $0.28, cents better than the analyst estimate of ($0.29). Revenue for the quarter was $2.46 million, which compares to the estimate of $2.97 million.
You May Also Be Interested In
- Shake Shack (SHAK) IPO Opens Up 124%
- Oracle (ORCL) Gains Could Accelerate on Further Enterprise Cloud Push
- Two Briggs & Stratton (BGG) Directors Buy Stock
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!